Understanding RSV and Why It’s a Threat to Seniors

Respiratory syncytial Virus (RSV) is a common respiratory virus that usually causes ⁣mild, cold-like symptoms. Though, for older adults, RSV can ‍lead to severe illness, including pneumonia and hospitalization. Before the availability‍ of a vaccine, RSV was estimated to cause approximately ‌60,000-160,000 ⁤hospitalizations and 6,000-10,000 ‌deaths annually among ⁤adults 65 years and older in the United States. The virus weakens the respiratory‍ system, making individuals more vulnerable to⁢ secondary​ infections​ and exacerbating existing conditions like chronic obstructive‌ pulmonary disease (COPD) and heart failure.

The vulnerability of older adults stems from age-related decline in immune function (immunosenescence) and the presence of underlying health ⁣conditions. This makes them less able to fight off the virus effectively,​ leading to more ⁣severe symptoms and complications.

The Arexvy vaccine: How it effectively works and Trial⁢ Results

Arexvy, developed by GSK, is a recombinant subunit⁣ vaccine containing a⁤ stabilized prefusion F protein. This protein ‍is found on the surface of the ‌RSV virus and is crucial for the virus to enter cells. By presenting this protein to the immune system, the vaccine triggers the production of​ antibodies ⁢that can neutralize the virus and‌ prevent infection.

The pivotal Phase 3 trial, published in the New England Journal of Medicine on November 13, 2025, ‍involved over 12,600 adults aged 60 years ⁢and older. ‌ The results demonstrated a vaccine efficacy of 82.6% against RSV-associated lower respiratory tract disease⁤ (LRTD) -​ defined as having at least two symptoms⁢ including cough,shortness ⁤of breath,wheezing,or fever. The vaccine also showed efficacy against severe LRTD, with a​ 94.1% reduction in cases requiring hospitalization.

Importantly, the trial also assessed safety. While some participants experienced mild to moderate side effects such as pain at the injection site, fatigue, and muscle aches,⁤ serious adverse events were rare and ‌not⁤ considerably different⁤ between the vaccine and placebo groups. A small number of participants experienced Guillain-Barré syndrome, a rare neurological disorder, but the causal relationship to the vaccine remains under investigation.

Who ‌Should Get the RSV Vaccine?

The Centers ⁤for Disease ⁣Control and Prevention (CDC) recommends that adults aged 60 years ‍and older may receive a dose of RSV vaccine, based on shared clinical decision-making with thier healthcare provider. This means that individuals should discuss the⁤ benefits and risks of vaccination with their doctor to determine if it’s right for them.

Those who may ‌particularly benefit include:

• Individuals with chronic heart ⁤or lung disease
• People with weakened immune systems
• Those with diabetes
• Adults living in long-term care facilities

It’s crucial to note that the ​RSV vaccine is not a substitute for other preventive measures,such as practicing good hygiene (handwashing,covering coughs and sneezes) and staying home when sick.

Timeline of RSV Vaccine Progress